We use cookies to ensure our website works properly and to personalise your experience. Cookies policy
Department of Biological Science, Birla Institute of Technology and Science, Pilani, Hyderabad Campus, India
The convergence of high-throughput omics technologies has ushered in a new era of precision medicine, enabling the comprehensive characterization of disease biology and the development of individualized treatment strategies. Traditionally, omics layers such as genomics, transcriptomics, proteomics, and metabolomics were analysed in isolation, limiting their clinical utility. However, recent advances in integrative computational approaches and biological modelling have shifted the paradigm toward systems biology, where multi-omics data are collectively analysed to capture dynamic, multilayered regulatory networks. This evolution has transformed our understanding of disease pathogenesis, therapeutic response, and resistance mechanisms. This review presents a detailed exploration of how multi-omics is being applied in modern precision medicine, with a particular focus on the growing importance of single-cell and spatial omics technologies. These modalities offer cell-type-specific and spatially resolved molecular insights, revealing hidden heterogeneity and functional interactions that influence drug efficacy. We discuss the mechanistic role of each omics layer, the interplay among layers, and emerging computational methods, including AI-based models and causal inference frameworks, that enable actionable insights from complex datasets. Furthermore, we highlight clinical case studies and translational advances demonstrating multi-omics applications in cancer therapy, immunotherapy, and microbiome modulation. Challenges related to data integration, standardization, privacy, and inclusion are also examined, along with future directions such as real-time liquid biopsy analysis and decision-support platforms. By tracing the transition from fragmented data analysis to unified, patient-centric frameworks, this review highlights the pivotal role of the multi-omics in shaping the next generation of personalized healthcare.
Precision medicine represents a transformative shift in healthcare, aiming to tailor treatment and prevention strategies to the unique biological makeup of each individual. This approach recognizes that diseases, particularly complex disorders such as cancer, autoimmune conditions, and metabolic syndromes, are not monolithic entities but rather heterogeneous processes shaped by genomic, molecular, environmental, and lifestyle factors. Central to the success of precision medicine is the ability to unravel this heterogeneity at multiple biological scales, a task increasingly enabled by multi-omics technologies.1 Multi-omics refers to the integrative analysis of diverse omics data types, including genomics, epigenomics, transcriptomics, proteomics, metabolomics, and others, to provide a comprehensive view of cellular and physiological processes. Each omics layer captures distinct dimensions of biological regulation: the genome provides the blueprint, the epigenome modulates gene accessibility, the transcriptome reflects dynamic gene activity, the proteome encodes functional effectors, and the metabolome represents the biochemical state of the cell. When combined, these layers offer synergistic insights into disease mechanisms, treatment response, and systems-level interactions that cannot be inferred from any single modality alone.2 Historically, the analysis of omics data has been siloed, with each layer investigated independently due to technological limitations, data incompatibility, and lack of integrative frameworks. Genomic studies have identified mutations linked to disease susceptibility and potential therapy targets, while transcriptomics has revealed gene expression signatures associated with prognosis. However, such isolated analyses often failed to account for downstream regulatory events, post-translational modifications, and metabolic alterations that critically influence phenotype. The emergence of integrative bioinformatics tools, advances in sequencing and mass spectrometry, and the establishment of public consortia such as TCGA, CPTAC, and ICGC have collectively catalysed a shift toward truly multi-dimensional analysis.3 In parallel, novel experimental technologies—most notably single-cell omics and spatial transcriptomics—have enabled the dissection of molecular heterogeneity at unprecedented resolution. These tools enable researchers to capture cell-type-specific and location-specific molecular profiles, revealing how the tumour microenvironment, immune landscape, and intercellular interactions influence treatment outcomes. Such insights are increasingly informing the design of adaptive therapies, combination regimens, and biomarker-driven clinical trials.4 This review aims to provide an in-depth synthesis of the current state and future directions of multi-omics in precision medicine. We begin by examining the biological contributions and limitations of individual omics layers, followed by a discussion of their interconnections through systems biology and trans-omics approaches. Subsequent sections explore the landscape of computational integration strategies, AI-driven predictive models, and case studies where multi-omics has informed clinical decision-making. Special emphasis is placed on single-cell and spatial technologies, the microbiome, and time-series omics, as well as the ethical, legal, and social dimensions of implementing these tools in real-world settings. By offering a holistic overview grounded in both mechanistic biology and translational science, this review underscores how multi-omics is poised to drive the next generation of predictive, preventative, and personalized healthcare.
Manish Khairnar*, Siddhesh Marda, Integrative Multi-Omics in Precision Medicine: From Molecular Interconnectivity to Single-Cell Resolution, Int. J. Sci. R. Tech., 2025, 2 (7), 162-186. https://doi.org/10.5281/zenodo.15831126
10.5281/zenodo.15831126